<bill session="114" type="h" number="2438" updated="2015-08-08T06:39:41-04:00">
  <state datetime="2015-05-19">REFERRED</state>
  <status>
    <introduced datetime="2015-05-19"/>
  </status>
  <introduced datetime="2015-05-19"/>
  <titles>
    <title type="official" as="introduced">To amend the Federal Food, Drug, and Cosmetic Act with respect to broader application of Bayesian statistics and adaptive trial designs.</title>
  </titles>
  <sponsor id="412563"/>
  <cosponsors/>
  <actions>
    <action datetime="2015-05-19" state="REFERRED">
      <text>Referred to the House Committee on Energy and Commerce.</text>
    </action>
    <action datetime="2015-05-22">
      <text>Referred to the Subcommittee on Health.</text>
    </action>
  </actions>
  <committees>
    <committee code="HSIF" name="House Energy and Commerce" activity="Referral"/>
    <committee activity="Referral" code="HSIF14" subcommittee="Health" name="House Energy and Commerce"/>
  </committees>
  <relatedbills>
    <bill relation="unknown" session="114" type="h" number="6"/>
  </relatedbills>
  <subjects>
    <term name="Health"/>
    <term name="Administrative law and regulatory procedures"/>
    <term name="Department of Health and Human Services"/>
    <term name="Drug safety, medical device, and laboratory regulation"/>
    <term name="Food and Drug Administration (FDA)"/>
    <term name="Medical research"/>
  </subjects>
  <amendments/>
  <summary>5/19/2015--Introduced.
This bill requires the Food and Drug Administration to issue guidance that addresses using alternative statistical methods, including adaptive trial design and Bayesian methods, in clinical trials and in the development and review of drugs and biological products.</summary>
</bill>
